Sina Naserian

Title: **Inventor Spotlight: Sina Naserian**

Introduction

Sina Naserian, located in Saint Maur des Fosses, France, is a notable innovator in the field of medical research. With a focus on hematologic malignancies, she has made significant contributions through her pioneering invention, which aims to improve treatment outcomes for patients facing these challenging conditions.

Latest Patents

Sina Naserian holds a patent titled "Prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist." This innovative approach involves the use of an anti-TNFR2 antagonist antibody aimed at preventing or treating relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or a treatment involving lymphocytes. Furthermore, her invention has implications for enhancing graft-versus-leukemia activity (GVL activity) in hematopoietic stem cell transplantation (HCT) or lymphocyte treatments.

Career Highlights

Throughout her career, Sina Naserian has made impactful contributions while working with prestigious institutions such as Université Paris Est Créteil Val De Marne and l’Institut National de la Santé et de la Recherche Médicale (INSERM). Her expertise and dedication have positioned her as a vital player in the medical research community pertaining to hematologic ailments.

Collaborations

Sina has effectively collaborated with esteemed colleagues, including Sébastien Maury and José Cohen. These partnerships have facilitated the advancement of research that aims to improve patient care and therapeutic strategies in the realm of hematologic malignancies.

Conclusion

Sina Naserian’s work exemplifies the vital role of innovation and collaboration in advancing medical research. Her commitment to developing effective treatments for hematologic malignancies underscores the importance of inventors in transforming healthcare and improving patient outcomes. Through her patent and ongoing efforts, she continues to contribute significantly to this essential field.